IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	enasidenib Sensitive: A1 - Approval enasidenib Sensitive : A1	enasidenib Sensitive: A1 - Approval enasidenib Sensitive : A1
IDH2 mutation	Oligodendroglioma	IDH2 mutation	Oligodendroglioma	vorasidenib Sensitive: A1 - Approval vorasidenib Sensitive : A1	vorasidenib Sensitive: A1 - Approval vorasidenib Sensitive : A1
IDH2 mutation	Astrocytoma	IDH2 mutation	Astrocytoma	vorasidenib Sensitive: A1 - Approval vorasidenib Sensitive : A1	vorasidenib Sensitive: A1 - Approval vorasidenib Sensitive : A1
IDH1 mutation	Astrocytoma	IDH1 mutation	Astrocytoma	vorasidenib Sensitive: A1 - Approval vorasidenib Sensitive : A1	vorasidenib Sensitive: A1 - Approval vorasidenib Sensitive : A1
IDH1 mutation	Oligodendroglioma	IDH1 mutation	Oligodendroglioma	vorasidenib Sensitive: A1 - Approval vorasidenib Sensitive : A1	vorasidenib Sensitive: A1 - Approval vorasidenib Sensitive : A1
IDH2 R172	Acute Myelogenous Leukemia	IDH2 R172	Acute Myelogenous Leukemia	enasidenib Sensitive: B - Late Trials enasidenib Sensitive : B	enasidenib Sensitive: B - Late Trials enasidenib Sensitive : B
IDH2 mutation	Glioma	IDH2 mutation	Glioma	vorasidenib Sensitive: B - Late Trials vorasidenib Sensitive : B	vorasidenib Sensitive: B - Late Trials vorasidenib Sensitive : B
IDH1 mutation	Glioma	IDH1 mutation	Glioma	vorasidenib Sensitive: B - Late Trials vorasidenib Sensitive : B	vorasidenib Sensitive: B - Late Trials vorasidenib Sensitive : B
IDH2 mutation	Acute Lymphocytic Leukemia	IDH2 mutation	Acute Lymphocytic Leukemia	enasidenib Sensitive: B - Late Trials enasidenib Sensitive : B	enasidenib Sensitive: B - Late Trials enasidenib Sensitive : B
IDH2 R140	Acute Myelogenous Leukemia	IDH2 R140	Acute Myelogenous Leukemia	enasidenib Sensitive: C2 – Inclusion Criteria enasidenib Sensitive : C2	enasidenib Sensitive: C2 – Inclusion Criteria enasidenib Sensitive : C2
IDH2 mutation	Myelodysplastic Syndrome	IDH2 mutation	Myelodysplastic Syndrome	enasidenib Sensitive: C2 – Inclusion Criteria enasidenib Sensitive : C2	enasidenib Sensitive: C2 – Inclusion Criteria enasidenib Sensitive : C2
IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	venetoclax + enasidenib Sensitive: C3 – Early Trials venetoclax + enasidenib Sensitive : C3	venetoclax + enasidenib Sensitive: C3 – Early Trials venetoclax + enasidenib Sensitive : C3
FLT3-ITD mutation + IDH2 mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation + IDH2 mutation	Acute Myelogenous Leukemia	IDH2 inhibitor Sensitive: C3 – Early Trials IDH2 inhibitor Sensitive : C3	IDH2 inhibitor Sensitive: C3 – Early Trials IDH2 inhibitor Sensitive : C3
MYC overexpression + IDH2 mutation	Acute Myelogenous Leukemia	MYC overexpression + IDH2 mutation	Acute Myelogenous Leukemia	enasidenib Resistant: C3 – Early Trials enasidenib Resistant : C3	enasidenib Resistant: C3 – Early Trials enasidenib Resistant : C3
MYC overexpression + IDH1 mutation	Acute Myelogenous Leukemia	MYC overexpression + IDH1 mutation	Acute Myelogenous Leukemia	enasidenib Resistant: C3 – Early Trials enasidenib Resistant : C3	enasidenib Resistant: C3 – Early Trials enasidenib Resistant : C3
IDH2 R140Q	Acute Myelogenous Leukemia	IDH2 R140Q	Acute Myelogenous Leukemia	venetoclax + enasidenib Sensitive: C3 – Early Trials venetoclax + enasidenib Sensitive : C3	venetoclax + enasidenib Sensitive: C3 – Early Trials venetoclax + enasidenib Sensitive : C3
IDH2 R172K	Acute Myelogenous Leukemia	IDH2 R172K	Acute Myelogenous Leukemia	venetoclax + enasidenib Sensitive: C3 – Early Trials venetoclax + enasidenib Sensitive : C3	venetoclax + enasidenib Sensitive: C3 – Early Trials venetoclax + enasidenib Sensitive : C3
IDH2 R172K	Acute Myelogenous Leukemia	IDH2 R172K	Acute Myelogenous Leukemia	TQB3455 Sensitive: C3 – Early Trials TQB3455 Sensitive : C3	TQB3455 Sensitive: C3 – Early Trials TQB3455 Sensitive : C3
IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	TQB3455 Sensitive: C3 – Early Trials TQB3455 Sensitive : C3	TQB3455 Sensitive: C3 – Early Trials TQB3455 Sensitive : C3
IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	venetoclax + enasidenib Sensitive: C3 – Early Trials venetoclax + enasidenib Sensitive : C3	venetoclax + enasidenib Sensitive: C3 – Early Trials venetoclax + enasidenib Sensitive : C3
IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	venetoclax + enasidenib + decitabine/cedazuridine Sensitive: C3 – Early Trials venetoclax + enasidenib + decitabine / cedazuridine Sensitive : C3	venetoclax + enasidenib + decitabine/cedazuridine Sensitive: C3 – Early Trials venetoclax + enasidenib + decitabine / cedazuridine Sensitive : C3
IDH2 mutation	Hematological Malignancies	IDH2 mutation	Hematological Malignancies	venetoclax + enasidenib Sensitive: C3 – Early Trials venetoclax + enasidenib Sensitive : C3	venetoclax + enasidenib Sensitive: C3 – Early Trials venetoclax + enasidenib Sensitive : C3
IDH2 R140Q + NPM1 mutation	Acute Myelogenous Leukemia	IDH2 R140Q + NPM1 mutation	Acute Myelogenous Leukemia	venetoclax + enasidenib Sensitive: D – Preclinical venetoclax + enasidenib Sensitive : D	venetoclax + enasidenib Sensitive: D – Preclinical venetoclax + enasidenib Sensitive : D
IDH1 R132H	Acute Myelogenous Leukemia	IDH1 R132H	Acute Myelogenous Leukemia	venetoclax + midostaurin + LY3410738 Sensitive: D – Preclinical venetoclax + midostaurin + LY3410738 Sensitive : D	venetoclax + midostaurin + LY3410738 Sensitive: D – Preclinical venetoclax + midostaurin + LY3410738 Sensitive : D
IDH2 R140Q	Acute Myelogenous Leukemia	IDH2 R140Q	Acute Myelogenous Leukemia	enasidenib Sensitive: D – Preclinical enasidenib Sensitive : D	enasidenib Sensitive: D – Preclinical enasidenib Sensitive : D
IDH2 R172G	Sarcoma	IDH2 R172G	Sarcoma	enasidenib Sensitive: D – Preclinical enasidenib Sensitive : D	enasidenib Sensitive: D – Preclinical enasidenib Sensitive : D
IDH1 mutation	Cholangiocarcinoma	IDH1 mutation	Cholangiocarcinoma	NMS-173 Sensitive: D – Preclinical NMS-173 Sensitive : D	NMS-173 Sensitive: D – Preclinical NMS-173 Sensitive : D

IDH2 inhibitor

IDH2 inhibitor

Associations(27)

Associations
(27)